Gefitinib in the treatment of the first relapse of prostate cancer beyond prostatectomy or radiotherapy
Study identifier:1839IL/0155
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An open label, non-comparative, phase II study of ZD1839 (Iressa) as first-line treatment in subjects with relapsed prostate cancer following radical prostatectomy or radiotherapy
Medical condition
prostate cancer
Phase
Phase 2
Healthy volunteers
No
Study drug
Gefitinib
Sex
Male
Actual Enrollment
30
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Dec 2003
Primary Completion Date: -
Study Completion Date: 01 Oct 2005
Study design
Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Finland Medical Director
AstraZeneca Finland
